Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29872603 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BEPHX1NQO2NPC1 | |
| SCHEMBL21591730 | 0.83 | NPC1 (0.43) | MTNR1AMTNR1BEPHX1NQO2NPC1 | |
| SCHEMBL31569211 | 0.83 | IDO1 (0.38) | EPHX1NQO2HPGDMEN1KMT2A | |
| SCHEMBL21594070 | 0.79 | MTNR1B (0.42) | MTNR1AMTNR1BNQO2HPGDALDH1A1 | |
| SCHEMBL21591738 | 0.78 | NQO2 (0.40) | MTNR1AMTNR1BNQO2HPGDALDH1A1 | |
| SCHEMBL29757579 | 0.74 | NPC1 (0.34) | NPC1RAB9A | |
| SCHEMBL21594073 | 0.74 | NPC1 (0.34) | NPC1RAB9A | |
| SCHEMBL23854682 | 0.74 | MTNR1B (0.45) | MTNR1AMTNR1BNQO2HPGDALDH1A1 | |
| SCHEMBL21594074 | 0.73 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL29757581 | 0.73 | NPC1 (0.36) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807270-B1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230219959-A1 | HYDRO-1H-PYRROLO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021099284-A1 | HYDRO-1H-PYRROLO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | MTNR1A 2976/4885MTNR1B 2298/4885EPHX1 1573/4885 |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, UACA, HLA-DRB1 | MTNR1A 3390/4885MTNR1B 2640/4885EPHX1 1335/4885 |
| US-20230219959-A1 | HYDRO-1H-PYRROLO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | AQP1, HRH2, HRH1 | MTNR1A 1144/4885MTNR1B 1234/4885EPHX1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.